Equities analysts forecast that Hill-Rom Holdings Inc (NYSE:HRC) will report sales of $695.42 million for the current fiscal quarter, Zacks Investment Research reports. Five analysts have issued estimates for Hill-Rom Holdings’ earnings. The lowest sales estimate is $690.10 million and the highest is $708.90 million. Hill-Rom Holdings reported sales of $655.40 million during the same quarter last year, which would suggest a positive year-over-year growth rate of 6.1%. The firm is expected to report its next quarterly earnings results before the market opens on Friday, July 28th.
On average, analysts expect that Hill-Rom Holdings will report full-year sales of $695.42 million for the current fiscal year, with estimates ranging from $2.75 billion to $2.79 billion. For the next financial year, analysts anticipate that the company will post sales of $2.90 billion per share, with estimates ranging from $2.86 billion to $2.93 billion. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side research firms that that provide coverage for Hill-Rom Holdings.
Hill-Rom Holdings (NYSE:HRC) last issued its earnings results on Friday, April 28th. The medical technology company reported $0.88 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.79 by $0.09. Hill-Rom Holdings had a return on equity of 19.77% and a net margin of 5.80%. The business had revenue of $678.90 million during the quarter, compared to analysts’ expectations of $654.27 million. During the same period in the prior year, the business earned $0.71 EPS. The business’s revenue for the quarter was up 7.3% compared to the same quarter last year.
HRC has been the subject of a number of recent analyst reports. Stifel Nicolaus lifted their price target on Hill-Rom Holdings from $70.00 to $84.00 and gave the stock a “buy” rating in a report on Monday, May 1st. Zacks Investment Research raised Hill-Rom Holdings from a “hold” rating to a “buy” rating and set a $87.00 price target for the company in a report on Friday, June 2nd. Barclays PLC lifted their price target on Hill-Rom Holdings from $80.00 to $86.00 and gave the stock an “overweight” rating in a report on Friday, June 9th. Finally, ValuEngine upgraded Hill-Rom Holdings from a “hold” rating to a “buy” rating in a research report on Friday, June 2nd. Five equities research analysts have rated the stock with a buy rating, The stock presently has a consensus rating of “Buy” and an average price target of $79.75.
In other news, SVP Paul Sherwood Johnson sold 2,078 shares of Hill-Rom Holdings stock in a transaction dated Wednesday, May 17th. The stock was sold at an average price of $72.30, for a total transaction of $150,239.40. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, SVP Andreas G. Frank sold 10,660 shares of Hill-Rom Holdings stock in a transaction dated Tuesday, June 6th. The stock was sold at an average price of $78.62, for a total value of $838,089.20. Following the sale, the senior vice president now owns 28,988 shares in the company, valued at approximately $2,279,036.56. The disclosure for this sale can be found here. 2.20% of the stock is currently owned by insiders.
Several hedge funds have recently bought and sold shares of HRC. Flinton Capital Management LLC purchased a new stake in Hill-Rom Holdings during the fourth quarter worth approximately $195,000. New York State Teachers Retirement System boosted its stake in Hill-Rom Holdings by 2.0% in the fourth quarter. New York State Teachers Retirement System now owns 104,667 shares of the medical technology company’s stock worth $5,876,000 after buying an additional 2,100 shares during the period. Renaissance Technologies LLC boosted its stake in Hill-Rom Holdings by 37.6% in the fourth quarter. Renaissance Technologies LLC now owns 427,700 shares of the medical technology company’s stock worth $24,011,000 after buying an additional 116,800 shares during the period. Pacad Investment Ltd. boosted its stake in Hill-Rom Holdings by 60.8% in the fourth quarter. Pacad Investment Ltd. now owns 8,200 shares of the medical technology company’s stock worth $460,000 after buying an additional 3,100 shares during the period. Finally, Bayesian Capital Management LP purchased a new stake in Hill-Rom Holdings during the fourth quarter worth approximately $740,000. Institutional investors and hedge funds own 84.18% of the company’s stock.
Shares of Hill-Rom Holdings (HRC) traded up 0.22% during midday trading on Friday, hitting $80.37. The company’s stock had a trading volume of 334,845 shares. Hill-Rom Holdings has a 12-month low of $47.76 and a 12-month high of $81.33. The firm has a 50-day moving average of $76.73 and a 200 day moving average of $67.09. The firm has a market cap of $5.29 billion, a price-to-earnings ratio of 34.72 and a beta of 1.23.
The company also recently announced a quarterly dividend, which will be paid on Friday, June 30th. Stockholders of record on Friday, June 16th will be given a dividend of $0.18 per share. This represents a $0.72 dividend on an annualized basis and a dividend yield of 0.90%. The ex-dividend date of this dividend is Wednesday, June 14th. Hill-Rom Holdings’s dividend payout ratio (DPR) is currently 31.03%.
Hill-Rom Holdings Company Profile
Hill-Rom Holdings, Inc is a global medical technology company. The Company operates through four segments: North America Patient Support Systems, International Patient Support Systems, Front Line Care and Surgical Solutions. The Company’s products and services include Patient Support Systems, Front Line Care and Surgical Solutions.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Hill-Rom Holdings Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hill-Rom Holdings Inc and related companies with our FREE daily email newsletter.